Kadcyla’s twelve-year reference exclusivity period ran out in February 2025. Adcetris lost its exclusivity years before that. Neither drug has […]
Zero for Two: Why No Antibody-Drug Conjugate Has Ever Faced a Biosimilar Read Post »
On March 26, 2026, the Patent Trial and Appeal Board ruled, again, that the Broad Institute invented CRISPR-Cas9 gene editing
On May 1, 2026, the company that made OxyContin stopped existing. Purdue Pharma dissolved and its pharmaceutical business restarted as
Stop Tracking Drug Patents. Start Tracking Who Controls Them. Read Post »
The Short Answer Google Patents is a free document index built for general-purpose prior art search. It has no connection
US Patent 11,530,197 B2 covers the compound that became rentosertib, the TNIK inhibitor that Insilico Medicine says is the first
No AI Has Ever Been Named Inventor on a Drug Patent. Here’s the Rule That Guarantees It. Read Post »
The FDA Orange Book does not link to the USPTO’s patent database. The USPTO’s patent database does not link to
The Free Patent Database Costing Your Team Thousands an Hour in Manual Cross-Referencing Read Post »
Eliquis has four expiration dates. Not one, not two. Four. The composition-of-matter patent covering apixaban was originally set to expire
A comprehensive freedom-to-operate analysis for a pharmaceutical asset takes four to twelve weeks and costs $50,000 to $200,000 in legal
On September 9, 2026, Bristol-Myers Squibb’s five-year new chemical entity (NCE) exclusivity for Sotyktu (deucravacitinib) reaches its four-year mark. That
Sign in or create a free account to read this DrugPatentWatch article
